The Epidermal Growth Factor Receptor – Tyrosine Kinase Inhibitor (EGFR-TKI), such as gefitinib, significantly extend survival and improve quality of life in NSCLC patients [3]. Here, EGFR is linked to non-small cell lung carcinoma.